Для цитирования:
Popov A., Henze G., Roumiantseva Y., Budanov O., Belevtsev M., Verzhbitskaya T., Boyakova E., Movchan L., Tsaur G., Fadeeva M., Lagoyko S., Zharikova L., Myakova N., Litvinov D., Khlebnikova O., Streneva O., Stolyarova E., Ponomareva N., Novichkova G., Fechina L., Aleinikova O., Karachunskiy A. Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022;21(2):95-104. https://doi.org/10.24287/1726-1708-2022-21-2-95-104
For citation:
Popov A., Henze G., Roumiantseva Yu., Budanov O., Belevtsev M., Verzhbitskaya T., Boyakova E., Movchan L., Tsaur G., Fadeeva M., Lagoyko S., Zharikova L., Myakova N., Litvinov D., Khlebnikova O., Streneva O., Stolyarova E., Ponomareva N., Novichkova G., Fechina L., Aleinikova O., Karachunskiy A. Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results. Pediatric Hematology/Oncology and Immunopathology. 2022;21(2):95-104. https://doi.org/10.24287/1726-1708-2022-21-2-95-104
Послать статью по эл. почте 
